| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/27/2005 | US6949584 use in inhibiting angiogenesis in a mammal |
| 09/27/2005 | US6949583 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same |
| 09/27/2005 | US6949580 Anticancer agents; restenosis; antiinflammatory agents; cardiovascular disorders |
| 09/27/2005 | US6949579 Central nervous system disorders; antidiabetic agents |
| 09/27/2005 | US6949578 useful in selectively inhibiting or antagonizing the alpha v beta 3 and/or alpha v beta 5 integrins; treatment of osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), angiogenesis |
| 09/27/2005 | US6949575 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives |
| 09/27/2005 | US6949567 Asymmetric amidine-substituted diphenylureas; diseases treated by the inhibition of intracellular protein degradation pathways, e.g. proteases, proteasome; anticarcinogenic agents; immunological modulators |
| 09/27/2005 | US6949566 For use as metalloproteinase inhibitors |
| 09/27/2005 | US6949565 Protein kinase inhibitors |
| 09/27/2005 | US6949561 polycyclic compound comprises sulphamate group attached to one of the ring components, wherein ring is naphtho(2,1-f)quinoline |
| 09/27/2005 | US6949559 Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| 09/27/2005 | US6949557 Hydroanthracene based compounds as anticancer agents |
| 09/27/2005 | US6949555 Use of organic compounds |
| 09/27/2005 | US6949547 Antidiabetic agents; central nervous system disorders; cardiovascular disorders; hypotensive agents; anticancer agents |
| 09/27/2005 | US6949546 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity |
| 09/27/2005 | US6949545 Tissue remodeling; antiinflammatory agents; autoimmune disease |
| 09/27/2005 | US6949544 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 09/27/2005 | US6949538 Compounds, compositions, and methods |
| 09/27/2005 | US6949535 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one |
| 09/27/2005 | US6949522 treating or preventing HIV infection, HBV infection or abnormal cellular proliferation by administering said compounds or the related beta -D and beta -L-2'-halo-4'-thionucleosides |
| 09/27/2005 | US6949515 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases |
| 09/27/2005 | US6949510 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 09/27/2005 | US6949366 Complexing; purified polypeptide |
| 09/27/2005 | US6949356 Methods for improving secondary metabolite production in fungi |
| 09/27/2005 | US6949337 Contacting human vpr interacting protein with a test compound and comparing the affinity of the vpr in the presence and absence of it |
| 09/27/2005 | US6949244 produced by hybridoma cell line ATCC No. HB 12020; elicits an immune response against (human milk fat globule) HMFG in non-human primates |
| 09/27/2005 | CA2428206C Methods for the treatment of cellular proliferative disorders |
| 09/27/2005 | CA2299355C Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| 09/27/2005 | CA2149120C Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof |
| 09/27/2005 | CA2122346C Bistriazenes as chemotherapeutic agents |
| 09/22/2005 | WO2005087783A1 Compositions comprising organometallic molybdenum compounds for treating cancer |
| 09/22/2005 | WO2005087778A1 Tricyclic furopyridine derivatives useful in the treatment of hyper-proliferative disorders |
| 09/22/2005 | WO2005087762A1 Novel indole derivative for alkylating specific base sequence of dna and alkylating agent and drug each comprising the same |
| 09/22/2005 | WO2005087743A1 Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors |
| 09/22/2005 | WO2005087269A1 Method of inhibiting tumor proliferation |
| 09/22/2005 | WO2005087252A1 Use of dm43 and its fragments as matrix metalloproteinases inhibitor |
| 09/22/2005 | WO2005087246A1 Antitumor agent |
| 09/22/2005 | WO2005087224A1 Composition for stabilizing epigallocatechin gallate (egcg) in water phase and preparation method thereof |
| 09/22/2005 | WO2005087221A1 Biodegradable biocompatible implant and method of manufacturing same |
| 09/22/2005 | WO2005027830A3 Chimeric transcription factor decoy oligonucleotides |
| 09/22/2005 | WO2005018580A3 Anti-cancer virus desensitization method |
| 09/22/2005 | WO2005002576A8 Imidazole derivatives and their use as protein kinases inhibitors |
| 09/22/2005 | WO2004060376A8 The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
| 09/22/2005 | WO2000075279A3 Nucleotide sequences for gene regulation and methods of use thereof |
| 09/22/2005 | US20050209463 Novel compound having antitumor activity and process for producing the same |
| 09/22/2005 | US20050209456 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents |
| 09/22/2005 | US20050209454 Synthetic process |
| 09/22/2005 | US20050209452 Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 09/22/2005 | US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/22/2005 | US20050209329 Potentiation of therapeutic effects of fatty acids |
| 09/22/2005 | US20050209325 Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| 09/22/2005 | US20050209316 Lactone formulations and method of use |
| 09/22/2005 | US20050209310 Methods for modulating tumor growth and metastasis |
| 09/22/2005 | US20050209292 Cancer therapy |
| 09/22/2005 | US20050209286 RXR activating molecules |
| 09/22/2005 | US20050209280 Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof |
| 09/22/2005 | US20050209267 Thioether substituted imidazoquinolines |
| 09/22/2005 | US20050209261 Rho-kinase inhibitors |
| 09/22/2005 | US20050209252 Using an indazole compound |
| 09/22/2005 | US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/22/2005 | US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/22/2005 | US20050209235 Tyrosine kinase inhibitors; antiproliferative agent; 2-(4-{4-[1-(3-Fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethyl}-[1,4]diazepan-1-yl)-ethanol combined with anticarncer agent selected from tamoxifen, toremifen, raloxifene, droloxifene, iodoxyfene, megestrol acetate and other |
| 09/22/2005 | US20050209229 Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib |
| 09/22/2005 | US20050209225 Substituted indoles and their use as integrin antagonists |
| 09/22/2005 | US20050209217 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors |
| 09/22/2005 | US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline |
| 09/22/2005 | US20050209214 1-oxa-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/22/2005 | US20050209192 Autoimmune disorders; modulating protein kinase C activity |
| 09/22/2005 | US20050209177 Combined use of genes that block oncogenic cell signalling pathways and chemotherapeutic and or radiotherapeutic agents |
| 09/22/2005 | US20050209174 Especially conjugating derivatives of paclitaxel, cholesterol, camptothecin, and rhodamine123 to transferrins, side effect reduction |
| 09/22/2005 | US20050209169 Respiratory disorders such as pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis |
| 09/22/2005 | US20050209161 Drugs for treatment of inflammation/blood brain barrier degradation;administering to a subject in need of such treatment, a pharmaceutically effective amount of a peptide antagonist of zonulin, wherein the peptide antagonist binds to a zonula occludens toxin receptor |
| 09/22/2005 | US20050209159 Effectors of dipeptidyl peptidase IV for topical use |
| 09/22/2005 | US20050209134 Novel depsipeptide compound |
| 09/22/2005 | US20050208619 29 human secreted proteins |
| 09/22/2005 | US20050208566 Using enzymatic membrane protein as tool in identifying modulators for prevention and treatment of atherosclerotic, inflammatory and cell proliferative disorders |
| 09/22/2005 | US20050208565 29 human cancer associated proteins |
| 09/22/2005 | US20050208546 Nucleotide sequences coding tumor associated antigens for use as tool in diagnosis, prevention and treatment of cell proliferative disorders |
| 09/22/2005 | US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response |
| 09/22/2005 | US20050208484 Isolated nucleic acid molecules encoding human drugmetobolizing proteins |
| 09/22/2005 | US20050208155 New DNA polymerase inhibitors, mikanolide and dihydromikanolide |
| 09/22/2005 | US20050208154 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily |
| 09/22/2005 | US20050208139 comprising Z isomeric form and E isomeric form of 4-hydroxy tamoxifen; not affected the drug potency; drug mixture in a gel, a solution, patch, in a unit dose packet or in a multiple dose container with a metered pump; new drug form; drug delivery device |
| 09/22/2005 | US20050208138 Injection of a biocompatible polymer, polysaccharide or polyamino acid, a cross-linker, and therapeutic agent into tumor; hydrogel formed in the tumor retains the therapeutic agent; drug delivery method; sustained releasing the biodrug |
| 09/22/2005 | US20050208137 comprising angiogenesis inhibitor retinoic acid, taxol and polymeric carrier polylactone; treating cancer, angiogenic-dependent diseases, embolizing blood vessels, and eliminating biliary, urethral, esophageal, tracheal/bronchial obstructions, corneal neovascularization; coated stents with the mixture |
| 09/22/2005 | US20050208136 Antitumor agent and process for producing the same |
| 09/22/2005 | US20050208135 Monocompartment osmotic controlled drug delivery system |
| 09/22/2005 | US20050208129 Prolonged release bioadhesive therapeutic systems |
| 09/22/2005 | US20050208125 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances |
| 09/22/2005 | US20050208122 Biodegradable biocompatible implant and method of manufacturing same |
| 09/22/2005 | US20050208065 Immunogenic compositions for induction of anti-tumor immunity |
| 09/22/2005 | US20050208064 Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide |
| 09/22/2005 | US20050208056 Neoplasm specific antibodies and uses thereof |
| 09/22/2005 | US20050208046 TWEAK receptor |
| 09/22/2005 | US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin |
| 09/22/2005 | US20050208040 Polynucleotides and polypeptides encoded thereby |
| 09/22/2005 | US20050208033 Induction of cell apoptosis of colon cancer; anticancer agent is 5 fluoro-uracil; bacterial strain is in a live or irradiated form |
| 09/22/2005 | US20050208024 Treating cancer in humans; obtain human, administer antitumor agent, evaluate tumor response to antitumor agents |
| 09/22/2005 | US20050207976 High energy phototherapeutic agents |
| 09/22/2005 | US20050207975 administering monoclonal Tac-antibodies; anticarcinogenic agents; immunotherapy |